OncoMatch/Clinical Trials/NCT07172204
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
Is NCT07172204 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Alternately treated with VA/low CHA regimen for intensive chemotherapy unfit.
Treatment: Alternately treated with VA/low CHA regimen — This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: FLT3 itd mutation
Prior therapy
Cannot have received: aml-directed therapy
Exception: cytoreduction for hyperleukocytosis per institutional guidelines (hydroxyurea, leukapheresis); supportive growth factors
Lab requirements
Kidney function
severe renal insufficiency requiring dialysis
Liver function
child-pugh b or c cirrhosis, or hepatic impairment with total bilirubin >1.5×uln
Cardiac function
severe heart failure (congestive heart failure requiring treatment or myocardial infarction history with ejection fraction ≤50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07172204 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with FLT3 alterations eligible?
No. FLT3 itd mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages